DoD Prostate Cancer Impact Award | Apply Online

FAQs: DOD Prostate Cancer Research Program (PCRP) Impact Award

What is the PCRP Impact Award?

The Department of Defense (DOD) Prostate Cancer Research Program (PCRP) Impact Award is a competitive funding opportunity intended to support prostate cancer research projects that could meaningfully change the field. The emphasis is on work that goes beyond incremental findings and, if successful, could substantially reduce deaths from prostate cancer and improve quality of life for men affected by the disease.

What does the program mean by “impact”?

“Impact” is the central lens used to evaluate applications. Applicants are expected to make a direct and explicit case for how the proposed research could create a major advance in an area of paramount importance in prostate cancer. The application needs to clearly explain what changes if the project succeeds, why that change matters, and how it addresses a critical need in research and/or patient care.

Is this award intended for incremental research advances?

No. This mechanism is positioned for projects that tackle major scientific or clinical problems in prostate cancer and can clearly argue why the work matters at a high level. The goal is to back research that could deliver a substantial leap forward rather than another small step.

How competitive has the Impact Award been historically?

It has historically been selective. Since it was first introduced in FY10, the program received 157 applications and 23 were recommended for funding (based on the information provided here).

What kinds of prostate cancer research are supported (basic, translational, clinical)?

The program supports the full spectrum of research, including basic laboratory studies, translational research, and clinical research, including clinical trials. The key requirement across the spectrum is that the project presents a credible route to eventual clinical impact for individuals with prostate cancer or those at risk.

Are clinical trials allowed under this award?

Yes, clinical trials are allowed, but they are limited to small-scale efforts up to and including Phase II (or equivalent).

Does the proposed research need to provide immediate benefit to patients?

Immediate patient benefit is not required. However, proposals cannot stop at discovery alone. Even for basic or early-stage work, the application must articulate a credible pathway toward improving prevention, diagnosis, prognosis, or treatment for prostate cancer.

What is expected of the Principal Investigator (PI) in the application?

The PI is expected to do more than describe strong scientific methods. The application should explicitly spell out the high-level importance of the work: what would change if it works, why that change is significant, and how the project addresses a critical gap in prostate cancer research and/or patient care.

Do applicants need to align with PCRP priorities?

Applicants are strongly encouraged to align their proposals with one of the PCRP overarching challenges and are expected to address at least one PCRP focus area.

What if a project does not map neatly onto a PCRP overarching challenge?

If the project does not map cleanly to an overarching challenge, the application must still justify how it fills an urgent gap in the field and why it should be considered high-impact anyway.

Is preliminary data required?

Yes. Applicants must include preliminary data to demonstrate feasibility.

Are there restrictions on unpublished preliminary data included in the application?

Yes. Any unpublished preliminary results included in the application are expected to come from the PI’s laboratory or from members of the research team. This reinforces that proposals should be grounded in demonstrated capability rather than purely speculative plans.

What does the solicitation suggest about study design quality and credibility?

The solicitation points to elements that strengthen rigor and credibility where appropriate, including cell line authentication, strong statistical rigor in preclinical animal experiments, and experiments designed to test clinical relevance and translatability.

Are there specific resources mentioned for strengthening human relevance or access to specimens/data?

Yes. The announcement highlights PCRP-funded resources that can strengthen human relevance when retrospectively collected human specimens or correlated clinical data are important. Two resources specifically named are the Prostate Cancer Biorepository Network (PCBN) and the North Carolina-Louisiana Prostate Cancer Project (PCaP).

Does the program encourage use of large patient datasets and long-term records?

Yes. The opportunity encourages studies that leverage large patient datasets with long-term health records and biospecimen repositories, especially when paired with modern genomic/proteomic approaches, bioinformatics, and mathematical modeling.

Are population science approaches encouraged?

Yes. Population science-based approaches are called out as particularly encouraged, reflecting interest in research that can address outcomes at scale, disparities, risk, and real-world patterns of disease.

Who is eligible to apply?

Eligibility is described as broadly open and not restricted by organization type, subject to any specific clarifications in the full notice (as referenced in the information provided).

When was this opportunity posted and when did it close?

The opportunity was posted on May 5, 2016, by DOD-AMRAA, and had a closing date of August 25, 2016.

What types of funding instruments are used for awards?

Funding instruments listed include both grants and cooperative agreements.

What is the CFDA number associated with this opportunity?

The opportunity is listed under CFDA 12.420 (Science and Technology and other Research and Development).

How many awards were anticipated?

The notice anticipated making about 8 awards.

Is there a stated maximum award amount (award ceiling)?

An award ceiling is referenced in the listing, but the specific dollar cap is not provided in the information supplied here.

What is the overall “fit” for a strong Impact Award application?

Based on the description provided, the program is positioned for teams with a well-supported and clearly justified plan aimed at a major advance in prostate cancer research, backed by preliminary data, designed with credible rigor, and paired with a believable route to eventual clinical or public health benefit.